Kingsview Wealth Management LLC acquired a new position in Becton, Dickinson and Company (NYSE:BDX – Free Report) during the second quarter, Holdings Channel.com reports. The institutional investor acquired 36,685 shares of the medical instruments supplier’s stock, valued at approximately $5,551,000.
Other institutional investors have also added to or reduced their stakes in the company. Imprint Wealth LLC purchased a new stake in shares of Becton, Dickinson and Company in the third quarter worth approximately $25,000. SHP Wealth Management purchased a new position in Becton, Dickinson and Company during the 4th quarter valued at $26,000. Meeder Asset Management Inc. boosted its holdings in Becton, Dickinson and Company by 152.2% during the 1st quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock valued at $27,000 after acquiring an additional 102 shares during the period. Main Street Group LTD bought a new position in Becton, Dickinson and Company in the 1st quarter valued at $29,000. Finally, Bell Investment Advisors Inc bought a new position in Becton, Dickinson and Company in the 2nd quarter valued at $29,000. Institutional investors own 86.97% of the company’s stock.
Insider Buying and Selling at Becton, Dickinson and Company
In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,100 shares of the company’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total transaction of $160,226.00. Following the completion of the sale, the executive vice president owned 13,172 shares in the company, valued at $1,918,633.52. This represents a 7.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total value of $440,887.92. Following the sale, the executive vice president directly owned 14,856 shares in the company, valued at $2,686,559.04. This trade represents a 14.10% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 11,869 shares of company stock valued at $1,994,719 in the last ninety days. Company insiders own 0.40% of the company’s stock.
Wall Street Analyst Weigh In
Becton, Dickinson and Company Stock Performance
BDX stock opened at $189.71 on Friday. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $193.07. The business has a 50-day moving average price of $166.14 and a 200 day moving average price of $160.53. The company has a market capitalization of $52.27 billion, a P/E ratio of 57.14, a PEG ratio of 13.26 and a beta of 0.19. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51.
Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last issued its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.14 by $0.09. The company had revenue of $4.98 billion for the quarter, compared to analysts’ expectations of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The firm’s quarterly revenue was up 5.4% on a year-over-year basis. During the same period in the prior year, the business earned $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, equities research analysts forecast that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.
Becton, Dickinson and Company Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be paid a dividend of $1.05 per share. The ex-dividend date is Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 126.51%.
About Becton, Dickinson and Company
Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.
BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.
Featured Articles
- Five stocks we like better than Becton, Dickinson and Company
- 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
- IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
- Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
- Okta Stock Surges 29%—Is $200 the Next Stop?
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Free Report).
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.
